We are inspired by the difference that we can make in the lives of people through the innovative medicines that we discover and develop.
Proximagen Group plc (AIM:PRX) is focused on the development and commercialisation of novel therapeutics for diseases of the
central nervous system (CNS).
We are developing a broad pipeline of drug candidate programmes and have plans for substantial future growth through a strategy of acquisition and consolidation of innovative drug candidate programmes in diseases of the CNS. We believe that significant value creation opportunities can arise by building critical mass, reducing the cost base, and focusing resources on a more promising pipeline where tough decisions will be taken to discontinue weak programmes.
The Company's strong balance sheet makes us one of the best capitalised biotechnology companies in the small and mid cap European biotech sector.
Our Corporate Objectives:
|
Science first, always
We strive for true scientific innovations that break new ground in treatment. Using this standard as a development benchmark makes things more challenging, but demonstrates our commitment to pursuing only those opportunities that improve upon current therapies in meaningful ways and represent the best chance of generating significant commercial value.